Respiratory Research 2024; 25(1): 118 | Hong Xiaoning et al.
Asthma is the most common chronic disease in children characterized by airway inflammation in response to certain triggers, such as pollen, cold and other respiratory infections [1]. Asthma exacerbations are still the fourth leading cause of hospital...
BMC Pulmonary Medicine 2024; 24(1): 105 | Tsukada Akinari et al.
Coronavirus disease 2019 (COVID-19) is a global pandemic, with over 6 million deaths reported as of July 2023 [1]. The availability of treatments and development of vaccines have helped reduce the risk of severe cases, but the clinical characteristics...
BMC Palliative Care 2024; 23(1): 76 | Mendes M. Aurora et al.
Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) are among the most common non-communicable diseases worldwide [1]. They are leading causes of mortality and constitute 4.1% of disability-adjusted...
BMC Medical Informatics and Decision Making 2024; 24(1): 65 | Wu Robert et al.
There are 88,000 hospitalizations for COPD exacerbations in Canada annually with a readmission rate of 19–24% at 30 days and 35–43% at 90 days [1–4]. The cost of a COPD hospitalization is on average $10,000 [5]. Patients hospitalized...
Orphanet Journal of Rare Diseases 2024; 19(1): 170 | Shi Yumeng et al.
Anti-melanoma differentiation-associated gene 5 antibody positive (anti-MDA5) dermatomyositis (DM) is a specific subtype of DM and is also known as clinically amyopathic dermatomyositis (CADM). Anti-MDA5DM is characterized with subtle or no muscle involvement,...
BMC complementary medicine and therapies 2024; 24(1): 121 | Oura Keita et al.
Drug-induced interstitial lung disease (DIILD) is the most common drug-induced lung toxicity that occurs when drug exposure causes inflammation and, eventually, fibrosis of the lung interstitium [1, 2]. DIILD is a severe adverse event (AE) that leads...
By requesting access to the "Respiratory Science Alert" service, I agree that GNM Healthcare Group Companies USA, Inc. may use the data acquired during my access request to provide me with weekly
information related to its services in accordance with the
Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to
dpo@gnmhealthcare.com.
You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.
Respiratory Research 2024; 25(1): 118 | Hong Xiaoning et al.
